Compare CarMax, Inc (KMX) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CarMax, Inc vs Regeneron Pharmaceuticals Inc — how do they compare? CarMax, Inc trades at $52.61 (market cap $7.64B), while Regeneron Pharmaceuticals Inc trades at $746.54 (market cap $76.14B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 10× CarMax, Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while CarMax, Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold CarMax, Inc for 49 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| KMX | REGN | |
|---|---|---|
Market Cap | $7.64B | $76.14B |
Volume | 3,610,116 | 500,239 |
Sector | Consumer Cyclical | Health |
52-Week High | $64.22 | $852.03 |
52-Week Low | $30.88 | $557.73 |
Typical Hold Time | 49 Days | 107 Days |
Enterprise Value | $25.34B | $70.85B |
Dividend Yield | — | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CarMax (KMX) trades at $52.61, down 1.26% amid bearish technical signals despite recent earnings beats. The stock shows mixed fundamentals with a P/E of 25.37 and net margin of 1.06%, while revenue trends downward from $31.9B in 2022 to $26.4B in 2025. Recent Q2 2026 earnings of $1.16 per share beat expectations by 58%, driven by 19.5% revenue growth and improved unit sales under the 'Shift into GEAR' strategy.
The outlook remains cautious with analyst consensus at Hold (62%) and $58.89 price target suggesting 12% upside. Key risks include declining profit margins, high debt load ($18.14B long-term), and competitive pressures. Positive catalysts include continued execution of turnaround strategy and November 3 strategic update.
Regeneron Pharmaceuticals (REGN) trades at $746.54, up 0.6% on the day, with a bearish technical signal but strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront and milestone payments. Cash flow improved in 2025, and profitability remains robust with a net income margin of 27.86%.
The outlook is positive, driven by the expanded Sanofi partnership and promising clinical trial updates, though technical indicators suggest near-term resistance. Risks include competitive pressures in key drug markets and reliance on successful drug development. Analysts are bullish with a consensus price target of $849.84, indicating potential upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About CarMax, Inc
CarMax sells, finances, and services used and new cars through a chain of over 230 used retail stores. It was formed in 1993 as a unit of Circuit City and spun off into an independent company in late 2002. Used-vehicle sales typically account for about 83% of revenue and wholesale about 13%, with the remaining portion composed of extended service plans and repair. In fiscal 2022, the company retailed and wholesaled 924,338 and 706,212 used vehicles, respectively. CarMax is the largest used-vehicle retailer in the U.S. but still estimates that it has only about 4% U.S. market share of vehicles 0-10 years old in 2021. It seeks over 5% share by the end of calendar 2025 and revenue between $33 billion to $45 billion by fiscal 2026. CarMax is based in Richmond, Virginia.
Read more on KMX →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
